title: Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones.
abstract: Gynecological cancers such as breast, ovarian, and endometrial carcinoma express receptors for luteinizing hormone-releasing hormone (LHRH), bombesin/gastrin-releasing peptide (BN/GRP), and somatostatin (SST). These tumors are therefore suitable candidates for targeted therapy with cytotoxic hybrid molecules consisting of a cytotoxic radical and a peptide hormone analogue as a carrier. These compounds have been shown to be more active and less toxic in vivo than nontargeted chemotherapy in models of various human cancers which express the respective receptors. The current review summarizes experimental and clinical findings with cytotoxic peptide hormone analogues of LHRH (AN-152 [AEZS 108], AN-207), BN/GRP (AN-215), and SST (AN-238) in breast, ovarian, and endometrial cancers.
authors: Universitätsfrauenklinik Würzburg, Josef-Schneider-Strasse 4, 97080 Würzburg, Germany. joergbengel@hotmail.com
authors: Jörg B
authors: JB
authors: Engel
authors: Andrew V
authors: AV
authors: Schally
authors: Johannes
authors: J
authors: Dietl
authors: Lorenz
authors: L
authors: Rieger
authors: Arnd
authors: A
authors: Hönig
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D007987:Gonadotropin-Releasing Hormone / Q000737:chemistry / Q000633:toxicity; D006801:Humans; D015394:Molecular Structure; D036361:Peptide Hormones / Q000737:chemistry* / Q000633:toxicity*; D013379:Substrate Specificity; D014565:Urogenital Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology
chemical_list: D036361:Peptide Hormones; D007987:Gonadotropin-Releasing Hormone